DGAP-News

STADA Arzneimittel AG: Changes in the Executive Board of STADA Arzneimittel AG

DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous STADA Arzneimittel AG: Changes in the Executive Board of STADA Arzneimittel AG 23.01.2017 / 10:00 The issuer is solely responsible for the content of this announcement. Investor News Changes in the Executive Board of STADA Arzneimittel AG

- Dr. Barthold Piening responsible for Production, Research and Development, Biotechnology as well as Quality Assurance and Control

- New Executive Board remuneration system developed

Bad Vilbel, January 23, 2017 - The Supervisory Board of STADA Arzneimittel AG has appointed Dr. Barthold Piening as a full Member of the Executive Board with effect from July 1, 2017 at the latest. He will assume Executive Board responsibility for Production, Research and Development, Biotechnology as well as Quality Assurance and Control. Interim responsibility for these areas currently lies with Executive Board Chairman Dr. Matthias Wiedenfels and Chief Financial, Marketing and Sales Officer Helmut Kraft. The Supervisory Board also presented the newly developed system for Executive Board remuneration.

Dr. Piening (58) has extensive experience in a broad range of management positions in the pharmaceutical industry. He joins STADA from Swiss specialists for pharmaceutical dosage technology Acino, where he most recently served on the Executive Committee as Chief Operations Officer. Prior to that, Dr. Piening was Head of Global Operations at Takeda Pharmaceutical, held the position of Executive Vice President Operations at Nycomed and was responsible for various operational and strategic functions at Altana. Dr. Piening studied pharmacy in Kiel, Germany, where he also received his doctorate. He also has an Executive MBA from WHU Koblenz and Northwestern University in Chicago.

Ferdinand Oetker, Chairman of the Supervisory Board at STADA Arzneimittel AG commented: "We are extremely happy that we have been able to attract Dr. Piening, a proven expert, who will excellently complement the Executive Board team at STADA with his renowned expertise in efficient production management. We have thus established the scope necessary in the Executive Board to sustainably drive the initiated strategic development of the STADA Group forward."